Cargando…
GDP-Mannose Pyrophosphorylase: A Biologically Validated Target for Drug Development Against Leishmaniasis
Leishmaniases are neglected tropical diseases that threaten about 350 million people in 98 countries around the world. In order to find new antileishmanial drugs, an original approach consists in reducing the pathogenic effect of the parasite by impairing the glycoconjugate biosynthesis, necessary f...
Autores principales: | Pomel, Sébastien, Mao, Wei, Ha-Duong, Tâp, Cavé, Christian, Loiseau, Philippe M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6554559/ https://www.ncbi.nlm.nih.gov/pubmed/31214516 http://dx.doi.org/10.3389/fcimb.2019.00186 |
Ejemplares similares
-
Biochemical analysis of leishmanial and human GDP-Mannose Pyrophosphorylases and selection of inhibitors as new leads
por: Mao, Wei, et al.
Publicado: (2017) -
Alkyl-Resorcinol Derivatives as Inhibitors of GDP-Mannose Pyrophosphorylase with Antileishmanial Activities
por: Levaique, Hélène, et al.
Publicado: (2021) -
Minor Impact of A258D Mutation on Biochemical and Enzymatic Properties of Leishmania infantum GDP-Mannose Pyrophosphorylase
por: Mao, Wei, et al.
Publicado: (2022) -
In silico analysis of a therapeutic target in Leishmania infantum: the guanosine-diphospho-D-mannose pyrophosphorylase
por: Pomel, S., et al.
Publicado: (2012) -
GDP-Mannose Pyrophosphorylase B (GMPPB)-Related Disorders
por: Chompoopong, Pitcha, et al.
Publicado: (2023)